Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis
Authors
Tombal, BFLoriot, Y
Saad, F
McDermott, RS
Elliott, Tony
Rodriguez-Vida, A
Nole, F
Fournier, B
Collette, L
Gillessen, Silke
Affiliation
Universit� Catholique de Louvain, Brussels, BelgiumIssue Date
2019
Metadata
Show full item recordCitation
Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol. 2019;37(15_suppl):5007-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.5007Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5007Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.5007